FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for... Read More

SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company’s... Read More

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantly enhanced outcomes for patients on GLP-1 therapy, marking it as a promising supportive care... Read More

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All Cause Hospital Outpatient... Read More

SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024. Evoke will... Read More

SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company’s Board of Directors effective October 18, 2024. This appointment fulfills a condition set as part of the... Read More

Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it received approximately $3.0... Read More

SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administration... Read More

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that management will participate in the Gastroenterology and Hepatology Advanced Practice Providers Conference taking place from September 12 – 14, 2024 at the... Read More

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9 – 11, 2024 at the Lotte New York... Read More

GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs SOLANA... Read More

Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, together with... Read More

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that its board of directors (Board) has approved a 1-for-12 reverse stock split of the company's common stock. The reverse stock split will become effective at... Read More

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal... Read More

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW... Read More

114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal... Read More

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m. ET. Moderated by Yale Jen, PhD, Senior Managing Director of Equity Research at... Read More

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr.... Read More

Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for... Read More

SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes. Management will host a conference... Read More

SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of... Read More

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of... Read More

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug... Read More

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the... Read More

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA... Read More

SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA, a leading provider of global commercial services to the life... Read More

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its real-world healthcare utilization data suggesting reduced healthcare costs for patients on GIMOTI versus patients on oral metoclopramide will be presented,... Read More

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/366,829 pertaining to GIMOTI, the... Read More

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company... Read More

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation for Gastrointestinal Disorders (IFFGD) SOLANA BEACH, Calif. and CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.... Read More

SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Superiority of Nasal... Read More

SOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it will host a key opinion leader (KOL) webinar on June 22, 2023 at 11:00am ET to discuss the healthcare resource utilization data related to GIMOTI usage... Read More

Net product sales increased by 94% from Q1 2022 New cumulative prescribers up by 17% from Q4 2022 Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced its... Read More

SOLANA BEACH, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life... Read More

Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that the abstract entitled “Reducing... Read More

SOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug... Read More

SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title “Nasal Formulations of Metoclopramide.” This patent expires... Read More

SOLANA BEACH, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI covering its nasal formulation... Read More

SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA Life Science Service LLC, an independent provider of global... Read More

Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its... Read More

SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.... Read More

SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Reducing Real-World Healthcare... Read More

SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI ® patent infringement case (Civil Action No. 1:22-cv-02019) in the United States District... Read More

SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitled “Real-World Healthcare Resource Utilization of Patients Treated with Metoclopramide Nasal for Diabetic Gastroparesis (DGP)” will be... Read More

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.”... Read More

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled... Read More